BIOCRYST PHARMACEUTICALS's ticker is and the CUSIP is 09058V903. A total of 5 filers reported holding BIOCRYST PHARMACEUTICALS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,109,840 | +88.7% | 298,000 | +87.7% | 0.00% | – |
| Q2 2023 | $1,117,952 | -28.3% | 158,800 | -15.1% | 0.00% | -100.0% |
| Q1 2023 | $1,559,580 | -65.2% | 187,000 | -52.1% | 0.00% | -50.0% |
| Q4 2022 | $4,478,348 | -41.5% | 390,100 | -35.8% | 0.00% | -33.3% |
| Q3 2022 | $7,658,000 | +34.0% | 607,800 | +12.5% | 0.00% | +50.0% |
| Q2 2022 | $5,717,000 | – | 540,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 1,576 | $1,198,000 | 0.08% |
| GROUP ONE TRADING, L.P. | 17,900 | $136,000 | 0.00% |
| Citadel Advisors | 48,400 | $368,000 | 0.00% |